Unlocking The Potential Of Biosimilars With SGS: The Critical Role Of Comparative Analytical Assessments

Biosimilars are cost-effective alternatives to FDA-approved biologic products, providing treatments for various conditions like cancer and rheumatoid arthritis. They closely match reference products in safety, purity, potency, and effectiveness. Regulatory agencies advocate a methodical approach to biosimilar development, starting with thorough analytical comparisons.

SGS offers extensive expertise in analytical testing for Protein Therapeutic drug substances and products, meeting global regulatory standards. Our services include feasibility studies, method development, validation, routine testing, and stability assessments. Characterizing reference and proposed biosimilar products is crucial for regulatory approval, guiding the scope and strategy of comparative analytical assessments.

Discover the power of biosimilars and accelerate your path to licensing today by utilizing our expert analytical testing services to unlock the potential of biosimilars and bring cost-effective treatments to market faster.